Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Post-PCI Microcirculatory Dysfunction
NCT02507050Phase 4Withdrawn
- Sponsor
- Liverpool Heart and Chest Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivabradine in coronary artery disease (CAD) and angina pectoris (2 arms), sponsored by Liverpool Heart and Chest Hospital. Primary endpoint: Index of Microvascular Resistance. Planned start Mar 2016; status: withdrawn.
02
Drugs
ivabradine
03
Conditions
coronary artery disease (CAD)angina pectoris
Beyond the preview
Go deeper on NCT02507050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507050.